MA53872A - Variants du facteur de croissance de fibroblastes modifiés en tant qu'antagonistes du récepteur - Google Patents

Variants du facteur de croissance de fibroblastes modifiés en tant qu'antagonistes du récepteur

Info

Publication number
MA53872A
MA53872A MA053872A MA53872A MA53872A MA 53872 A MA53872 A MA 53872A MA 053872 A MA053872 A MA 053872A MA 53872 A MA53872 A MA 53872A MA 53872 A MA53872 A MA 53872A
Authority
MA
Morocco
Prior art keywords
growth factor
receptor antagonists
modified fibroblasts
factor variants
variants
Prior art date
Application number
MA053872A
Other languages
English (en)
Inventor
Jennifer Cochran
Sung Jin Park
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MA53872A publication Critical patent/MA53872A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA053872A 2018-10-09 2019-10-09 Variants du facteur de croissance de fibroblastes modifiés en tant qu'antagonistes du récepteur MA53872A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862743414P 2018-10-09 2018-10-09

Publications (1)

Publication Number Publication Date
MA53872A true MA53872A (fr) 2021-08-18

Family

ID=70163877

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053872A MA53872A (fr) 2018-10-09 2019-10-09 Variants du facteur de croissance de fibroblastes modifiés en tant qu'antagonistes du récepteur

Country Status (9)

Country Link
US (1) US20220249611A1 (fr)
EP (1) EP3863660A4 (fr)
JP (1) JP2022513178A (fr)
KR (1) KR20210091147A (fr)
CN (1) CN113194980A (fr)
AU (1) AU2019359295A1 (fr)
CA (1) CA3115772A1 (fr)
MA (1) MA53872A (fr)
WO (1) WO2020076987A2 (fr)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046399A2 (fr) * 2000-12-08 2002-06-13 The Board Of Trustees Of The University Of Illinois Proteines et complexes mutes du systeme majeur d'histocompatibilite de la classe i
US7790682B1 (en) * 2003-12-02 2010-09-07 The Florida State University Research Foundation, Inc. Engineered human acidic fibroblast growth factors and associated methods
EP1881067A1 (fr) * 2006-07-18 2008-01-23 Direvo Biotech AG Mannanases
MX2009012968A (es) * 2007-06-06 2010-04-01 Domantis Ltd Polipeptidos, dominios variables de anticuerpo y antagonistas.
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
US20160039896A1 (en) * 2009-01-18 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha v beta 3 integrin
US9023644B2 (en) * 2011-12-16 2015-05-05 Wisconsin Alumni Research Foundation FGF having enhanced stability
PL221356B1 (pl) * 2012-04-21 2016-03-31 Wrocławskie Ct Badań Eit & Spółka Z Ograniczoną Odpowiedzialności Zmodyfikowany genetycznie, rekombinowany czynnik wzrostu fibroblastów (FGF1) skoniugowany z nanocząsteczkami metalu lub tlenku metalu, jego sekwencja DNA i aminokwasowa oraz zastosowanie
US9290557B2 (en) * 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
JP2018535964A (ja) * 2015-10-30 2018-12-06 ソーク インスティテュート フォー バイオロジカル スタディーズ 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
WO2018018010A1 (fr) * 2016-07-21 2018-01-25 Metacrine, Inc. Mutants de fgf et leurs utilisations

Also Published As

Publication number Publication date
WO2020076987A2 (fr) 2020-04-16
US20220249611A1 (en) 2022-08-11
WO2020076987A3 (fr) 2020-06-04
KR20210091147A (ko) 2021-07-21
AU2019359295A1 (en) 2021-06-03
EP3863660A2 (fr) 2021-08-18
JP2022513178A (ja) 2022-02-07
CA3115772A1 (fr) 2020-04-16
CN113194980A (zh) 2021-07-30
EP3863660A4 (fr) 2022-07-06

Similar Documents

Publication Publication Date Title
MA51232A (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
MA46196A (fr) Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal
MA54547A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA54546A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA53835A (fr) Lactams bicycliques en tant qu'inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitment p.e. de maladies inflammatoires
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
MA53110A (fr) Composés polycycliques en tant qu'inhibiteurs de la tyrosine-kinase de bruton
IL277608B1 (en) Prodrugs of conjugated c5ar antagonists
MA47736A (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
MA52249A (fr) Antagonistes de l'intégrine humaine (alpha4) (beta7)
MA43817A (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
MA53218A (fr) Antagonistes de l'intégrine
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
MA52205A (fr) Protéines de fusion du facteur de différenciation de croissance 15
MA53643A (fr) Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6
IT201700100643A1 (it) Struttura di casseratura per l'esecuzione di getti per la realizzazione di solai
MA51998A (fr) Nouveaux polymorphes de sel de calcium en tant qu'agents anti-inflammatoires, immunomodulateurs et anti-prolifératifs
MA53474A (fr) Distribution de lingettes
MA50356A (fr) Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1
EA201890156A1 (ru) Антагонисты рецептора cgrp
IT201700093172A1 (it) Metodo per l'identificazione precoce di riacutizzazioni di broncopneumopatia cronica ostruttiva
MA51283A (fr) Dérivés de tyrosine en tant qu'inhibiteurs de kinase rho
MA51795A (fr) Oligonucléotides pour moduler l'expression de tmem106b
IT201900023235A1 (it) Impianto per la produzione di tessuto non tessuto
MA53872A (fr) Variants du facteur de croissance de fibroblastes modifiés en tant qu'antagonistes du récepteur